MX2020011355A - Metodo para la obtencion a gran escala de celulas t reguladoras tipo 1 aloespecificas humanas, estables en presencia de citocinas proinflamatorias con potencial terapeutico en trasplante. - Google Patents

Metodo para la obtencion a gran escala de celulas t reguladoras tipo 1 aloespecificas humanas, estables en presencia de citocinas proinflamatorias con potencial terapeutico en trasplante.

Info

Publication number
MX2020011355A
MX2020011355A MX2020011355A MX2020011355A MX2020011355A MX 2020011355 A MX2020011355 A MX 2020011355A MX 2020011355 A MX2020011355 A MX 2020011355A MX 2020011355 A MX2020011355 A MX 2020011355A MX 2020011355 A MX2020011355 A MX 2020011355A
Authority
MX
Mexico
Prior art keywords
cells
transplantation
alloe
pro
stable
Prior art date
Application number
MX2020011355A
Other languages
English (en)
Inventor
Gómez Josefina Alberú
Hernández Arimelek Cortés
MELGAREJO María Gloría SOLDEVILA
Cruz Saúl Arteaga
Katy Álvarez Salazar Evelyn
Original Assignee
Univ Mexico Nac Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mexico Nac Autonoma filed Critical Univ Mexico Nac Autonoma
Priority to MX2020011355A priority Critical patent/MX2020011355A/es
Priority to US17/510,902 priority patent/US20220127572A1/en
Publication of MX2020011355A publication Critical patent/MX2020011355A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención describe una metodología para obtener grandes números de células Tr1 humanas diferenciadas in vitro específicas para el (los) antígeno(s) del donante, con fenotipo y función supresora estable en presencia de citosinas proinflamatorias, mediante el cocultivo de células dendríticas tolerogénicas (DC10) derivadas de monocitos de un donador, con células T vírgenes de un receptor no relacionado genéticamente (alogénico). Las células obtenidas con el presente método expresan un fenotipo regulador Tr1 (CD4+, CD49b+, LAG-3+) son productoras de IL-10 y están enriquecidas en los receptores coinhibitorios PD1, TIM-3, CD39, CTLA-4 y TIGIT. Además, los Tr1 obtenidos tienen función supresora aloespecífica hacia los antígenos del donante. Estas células mantienen su fenotipo y función estable en presencia de las citosinas proinflamatorias IL-1ß, IL-6, IFN-? y TNF-a. El número, la pureza y la estabilidad de las Tr1 generadas, las convierte en candidatas para su uso como herramientas terapéuticas en el trasplante.
MX2020011355A 2020-10-26 2020-10-26 Metodo para la obtencion a gran escala de celulas t reguladoras tipo 1 aloespecificas humanas, estables en presencia de citocinas proinflamatorias con potencial terapeutico en trasplante. MX2020011355A (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2020011355A MX2020011355A (es) 2020-10-26 2020-10-26 Metodo para la obtencion a gran escala de celulas t reguladoras tipo 1 aloespecificas humanas, estables en presencia de citocinas proinflamatorias con potencial terapeutico en trasplante.
US17/510,902 US20220127572A1 (en) 2020-10-26 2021-10-26 Method for large-scale production of allospecific type 1 regulatory tregs (tr1) stable in the presence of proinflammatory cytokines with therapeutic potential in transplantation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2020011355A MX2020011355A (es) 2020-10-26 2020-10-26 Metodo para la obtencion a gran escala de celulas t reguladoras tipo 1 aloespecificas humanas, estables en presencia de citocinas proinflamatorias con potencial terapeutico en trasplante.

Publications (1)

Publication Number Publication Date
MX2020011355A true MX2020011355A (es) 2022-04-27

Family

ID=81258009

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011355A MX2020011355A (es) 2020-10-26 2020-10-26 Metodo para la obtencion a gran escala de celulas t reguladoras tipo 1 aloespecificas humanas, estables en presencia de citocinas proinflamatorias con potencial terapeutico en trasplante.

Country Status (2)

Country Link
US (1) US20220127572A1 (es)
MX (1) MX2020011355A (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8222033B2 (en) * 2002-08-12 2012-07-17 Argos Therapeutics, Inc. CD4+CD25− T cells and Tr1-like regulatory T cells
CA2652148C (en) * 2006-05-12 2016-10-04 Fondazione Centro San Raffaele Del Monte Tabor Tolerogenic dendritic cells, method for their production and uses thereof
US20150132272A1 (en) * 2012-06-18 2015-05-14 Yale University Compositions and methods for diminishing an immune response

Also Published As

Publication number Publication date
US20220127572A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
Putnam et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation
Trzonkowski et al. Ex vivo expansion of CD4+ CD25+ T regulatory cells for immunosuppressive therapy
Andolfi et al. Enforced IL-10 expression confers type 1 regulatory T cell (Tr1) phenotype and function to human CD4+ T cells
Bahri et al. Ectonucleotidase CD38 demarcates regulatory, memory-like CD8+ T cells with IFN-γ-mediated suppressor activities
Gregori et al. Clinical outlook for type-1 and FOXP3+ T regulatory cell-based therapy
Gaidot et al. Immune reconstitution is preserved in hematopoietic stem cell transplantation coadministered with regulatory T cells for GVHD prevention
Käser et al. Porcine regulatory T cells: mechanisms and T-cell targets of suppression
WO2015154012A8 (en) Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
RU2017111300A (ru) Центральные т-клетки памяти для адоптивной т-клеточной терапии
JP2018524987A5 (es)
Rossi et al. Immunologic microenvironment and personalized treatment in multiple myeloma
WO2019138217A1 (en) Method for transducing cells with a viral vector for the expression of a chimeric antigen receptor (car) or transgenic t-cell receptor (tcr)
Carretero-Iglesia et al. Comparative study of the immunoregulatory capacity of in vitro generated tolerogenic dendritic cells, suppressor macrophages, and myeloid-derived suppressor cells
Iwai et al. An IFN-γ-IL-18 signaling loop accelerates memory CD8+ T cell proliferation
MX2019000022A (es) Células veto generadas a partir de linfocitos t de memoria.
Mavers et al. High‐risk leukemia: Past, present, and future role of NK cells
Domaica et al. Human Natural Killer Cell Maturation Defect Supports In Vivo CD56bright to CD56dim Lineage Development
CY1123467T1 (el) Θεραπευτικο εμβολιο για τη θεραπεια του παιδικου διαβητη τυπου 1, εφαρμογη του κυτταροδιαχωριστη κυτταρομετριας ροης και της μεθοδου πολλαπλασιασμου των κυτταρων treg για την παραγωγη θεραπευτικου εμβολιου για τη θεραπεια του διαβητη τυπου 1
Berglund et al. Isolation, expansion and functional assessment of CD4+ CD25+ FoxP3+ regulatory T cells and Tr1 cells from uremic patients awaiting kidney transplantation
Käser et al. Current knowledge on porcine regulatory T cells
Gołąb et al. Impact of culture medium on CD4+ CD25highCD127lo/neg Treg expansion for the purpose of clinical application
Carluccio et al. Generation of tumor‐specific cytotoxic T‐lymphocytes from the peripheral blood of colorectal cancer patients for adoptive T‐cell transfer
MX2020011355A (es) Metodo para la obtencion a gran escala de celulas t reguladoras tipo 1 aloespecificas humanas, estables en presencia de citocinas proinflamatorias con potencial terapeutico en trasplante.
Besser et al. Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy
Xu et al. Depletion of CD4+ CD25high regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy